Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Eurofins Biomnis to Create Additional Capacity of 15,000 Tests Per Day Reported Within 24 Hours to Help Combat the Second Wave of the COVID-19 Pandemic


While France has been experiencing a second wave of COVID-19 infections for several weeks now, technicians and clinical pathologists at Eurofins Biomnis have worked round the clock to increase capacity for RT-PCR, the reference test to detect SARS-CoV-2 since March. The laboratory has deployed two very high throughput automated platforms to meet rising testing demand.

In order to analyse the maximum number of samples in the shortest possible time, 1000 m2 of laboratory space, dedicated to SARS-CoV-2 tests, has been established.

The platforms are composed of over one hundred instruments and equipment that manage samples in a process designed to be as automated as possible.

Since March, Eurofins Biomnis' testing capacity has been gradually ramped up to the point where it has now created spare capacity to test 15,000 samples per day in addition to its current volumes. The turnaround time for results is less than 24 hours in 99.8% of cases.

To meet demand, different teams work 24 hours a day, 7 days a week, which makes analyses validation possible even on Saturdays and Sundays. Should the number of tests increase beyond current available capacity, Eurofins Biomnis can collaborate with other laboratories within the Eurofins Group.

To learn more, please visit: https://www.eurofins.com/media-centre/press-releases/2020-10-16_1/ and Eurofins Biomnis

About Eurofins – the global leader in bio-analysis

Eurofins is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in esoteric and molecular clinical diagnostic testing.

With over 48,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201015006157/en/

Eurofins Scientific SE Stock

€57.54
0.810%
The Eurofins Scientific SE stock is trending slightly upwards today, with an increase of €0.46 (0.810%) compared to yesterday's price.
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Eurofins Scientific SE stock is not clear.
With a target price of 60 € there is a slightly positive potential of 4.28% for Eurofins Scientific SE compared to the current price of 57.54 €.
Like: 0
Share
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments